For X-ray diagnosis, the proper management of the entrance skin dose (ESD) is important. Recently, a small-type optically stimulated luminescence dosimeter (nanoDot OSL dosimeter) was made commercially available by Landauer, and it is hoped that it will be used for ESD measurements in clinical settings. Our objectives in the present study were to propose a method for calibrating the ESD measured with the nanoDot OSL dosimeter and to evaluate its accuracy. The reference ESD is assumed to be based on an air kerma with consideration of a well-known back scatter factor. We examined the characteristics of the nanoDot OSL dosimeter using two experimental conditions: a free air irradiation to derive the air kerma, and a phantom experiment to determine the ESD. For evaluation of the ability to measure the ESD, a calibration curve for the nanoDot OSL dosimeter was determined in which the air kerma and/or the ESD measured with an ionization chamber were used as references. As a result, we found that the calibration curve for the air kerma was determined with an accuracy of 5 %. Furthermore, the calibration curve was applied to the ESD estimation. The accuracy of the ESD obtained was estimated to be 15 %. The origin of these uncertainties was examined based on published papers and Monte-Carlo simulation. Most of the uncertainties were caused by the systematic uncertainty of the reading system and the differences in efficiency corresponding to different X-ray energies.

BPI calculated from measurement of multifrequency bioelectrical impedance analysis could evaluate whole body somatic protein stores, and is a potentially useful new marker assessing nutritional status in patients with chronic renal failure. Decreased body somatic protein stores, mainly due to muscle wasting, was prevalent in end-stage renal failure patients on maintenance dialysis.

Approximately 10 years have passed since the Peritoneal Dialysis Guidelines were formulated in 2009. Much evidence has been reported during the succeeding years, which were not taken into consideration in the previous guidelines, e.g., the next peritoneal dialysis PD trial of encapsulating peritoneal sclerosis (EPS) in Japan, the significance of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), the effects of icodextrin solution, new developments in peritoneal pathology, and a new international recommendation on a proposal for exit-site management. It is essential to incorporate these new developments into the new clinical practice guidelines. Meanwhile, the process of creating such guidelines has changed dramatically worldwide and differs from the process of creating what were “clinical practice guides.” For this revision, we not only conducted systematic reviews using global standard methods but also decided to adopt a two-part structure to create a reference tool, which could be used widely by the society’s members attending a variety of patients. Through a working group consensus, it was decided that Part 1 would present conventional descriptions and Part 2 would pose clinical questions (CQs) in a systematic review format. Thus, Part 1 vastly covers PD that would satisfy the requirements of the members of the Japanese Society for Dialysis Therapy (JSDT). This article is the duplicated publication from the Japanese version of the guidelines and has been reproduced with permission from the JSDT.

No abstract